Avalyn Pharma Inc. balance sheet AVLN

As of Jun 30, 2026, Avalyn Pharma Inc. had total assets of $425.4 million and total liabilities of $27.1 million. Stockholders' equity was $398.3 million. It held $413.5 million in cash and investments against $17.1 million of total debt, net cash of $396.4 million. The current ratio, current assets divided by current liabilities, was 33.12.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
Assets
Cash
264
Short-term investments
88
Long-term investments
61
Cash and investments
414
Total current assets
358
Property and equipment, net
1
Total assets
425
Liabilities and equity
Accounts payable
3
Total current liabilities
11
Total liabilities
27
Stockholders' equity
398
Debt
Long-term debt
15
Lease liabilities
2
Total debt
17
Net cash
396
Ratios
Current ratio
33.12x
Debt to equity
0.04x
Book value per share
8.99
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
AVLN (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boston, MA
SEC filer status
, Emerging growth company
SEC CIK
1540171
Former names
Genoa Pharmaceuticals, Inc. (until May 24, 2017)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.